Patients were followed for 10 years and median A1c levels were 7% in the intensively treated patients vs 7.9% in those who received conventional treatment. No differences in A1c levels were observed in individual therapies.
Significant reductions were observed in diabetes complications in the intensively treated groups compared with the conventionally treated group.
There was a reduction of 16% in MI in the intensive treatment group, which approached statistical significance (P=0.052).
Analysis of the data revealed that any reduction in A1c level is predictive of benefit to patients with type 2 diabetes.

American Diabetes Association. Diabetes Care. 1999;22(suppl 1):S27-S31.
UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.